Share This Page
Drug Price Trends for NDC 81952-0135
✉ Email this page to a colleague
Average Pharmacy Cost for 81952-0135
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 13.29407 | ML | 2025-04-23 |
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 13.08599 | ML | 2025-03-19 |
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 12.29180 | ML | 2025-02-19 |
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 10.91916 | ML | 2025-01-22 |
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 10.98246 | ML | 2024-12-18 |
| ENOXAPARIN 150 MG/ML SYRINGE | 81952-0135-06 | 8.25271 | ML | 2024-11-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 81952-0135
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 81952-0135
The pharmaceutical industry is constantly evolving, with new drugs entering the market and existing ones facing competition from generics and biosimilars. In this comprehensive analysis, we'll explore the market dynamics and price projections for the drug with National Drug Code (NDC) 81952-0135, examining various factors that influence its pricing and market position.
Understanding NDC 81952-0135
NDC 81952-0135 is a unique identifier for a specific drug product. The NDC system, maintained by the U.S. Food and Drug Administration (FDA), provides a standardized method for identifying human drugs in the United States[4]. This particular NDC belongs to a drug that falls under the category of incretin-based drugs, which are used in the treatment of type 2 diabetes.
The Role of Incretin-Based Drugs
Incretin-based drugs have gained significant attention in recent years due to their ability to manage hyperglycemia without the associated risks of hypoglycemia or weight gain[1]. These drugs work by mimicking or enhancing the action of incretin hormones, which play a crucial role in regulating blood sugar levels.
Global Incretin-Based Drugs Market Overview
The global incretin-based drugs market is experiencing robust growth, with projections indicating a promising future. According to recent market research:
Forecasts suggest that the Global Incretin Based Drugs market is set to flourish from 2024 through 2029, with an impressive CAGR of 6.8%. By 2029, the market valuation is projected to reach USD 64.28 billion, an escalation from the USD 40.72 billion recorded in 2022[1].
This significant growth is primarily driven by the increasing prevalence of type 2 diabetes worldwide, highlighting the critical need for advanced therapeutic options.
Regional Market Insights
The market for incretin-based drugs, including NDC 81952-0135, varies across different regions:
- Americas
- Europe
- Asia-Pacific (APAC)
- Middle East & Africa (MEA)
Each region presents unique opportunities and challenges for drug manufacturers and distributors. For instance, the United States, being one of the largest pharmaceutical markets globally, plays a crucial role in shaping the overall market dynamics for incretin-based drugs.
Factors Influencing Drug Pricing
Several factors contribute to the pricing of drugs like NDC 81952-0135:
1. Research and Development Costs
The high costs associated with drug development, including clinical trials and regulatory approvals, significantly impact the final pricing of pharmaceutical products.
2. Competition
The presence of competing drugs in the market, including both branded and generic alternatives, can influence pricing strategies.
3. Patent Protection
The duration of patent protection plays a crucial role in determining a drug's pricing strategy over time.
4. Regulatory Environment
Government regulations and healthcare policies can significantly impact drug pricing and market access.
5. Manufacturing and Distribution Costs
The expenses associated with producing and distributing the drug contribute to its overall cost structure.
Price Projections for NDC 81952-0135
While specific price projections for NDC 81952-0135 are not available in the provided search results, we can infer potential pricing trends based on the overall market dynamics for incretin-based drugs.
Short-term Outlook
In the short term, the price of NDC 81952-0135 is likely to remain stable or potentially increase, driven by the growing demand for incretin-based drugs and the overall market growth projected at a CAGR of 6.8%[1].
Long-term Considerations
Looking ahead, several factors could influence the long-term pricing of NDC 81952-0135:
- Patent expiration and potential generic competition
- Introduction of new, more advanced incretin-based drugs
- Changes in healthcare policies and reimbursement structures
- Advancements in diabetes treatment alternatives
Market Positioning and Competitive Landscape
The competitive landscape for incretin-based drugs is characterized by the presence of several key players:
- Eli Lilly and Company
- Boehringer Ingelheim
- Novo Nordisk
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer
- Novartis AG
- Takeda Pharmaceuticals
- Bristol Myers Squibb
- Structure Therapeutics[1]
These companies employ various strategies to maintain their market position and influence pricing:
Product Differentiation
Manufacturers focus on developing drugs with improved efficacy, safety profiles, or more convenient dosing regimens to differentiate their products from competitors.
Marketing and Branding
Effective marketing campaigns and strong brand recognition can help maintain market share and justify premium pricing.
Strategic Partnerships
Collaborations with other pharmaceutical companies or research institutions can lead to the development of innovative products and strengthen market position.
The Impact of Generic Competition
The entry of generic competitors can significantly impact the pricing and market share of branded drugs like NDC 81952-0135. Historical data from other drug markets suggest that generic entry often leads to price reductions and shifts in market dynamics.
Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition[2].
This observation highlights the need for manufacturers to anticipate and prepare for potential generic competition in their long-term pricing strategies.
The Role of Insurance and Reimbursement
Insurance coverage and reimbursement policies play a crucial role in determining the actual cost of drugs to patients and their market uptake. For incretin-based drugs like NDC 81952-0135, favorable insurance coverage can significantly impact market penetration and pricing strategies.
Tiered Prescription Drug Coverage
Many insurance plans in the United States offer tiered prescription drug coverage, which can influence the pricing and market share of different drugs within the same therapeutic class[2].
Medicaid and Medicare Impact
Government programs like Medicaid and Medicare have a substantial influence on drug pricing and market dynamics. For instance:
Medicaid accounted for nearly 20% of all prescription drug expenditures in the U.S. Thus, distortions in the market for drugs purchased by Medicaid have potentially large impacts on overall drug spending, and health care spending more generally[3].
Future Market Trends and Innovations
The market for incretin-based drugs, including NDC 81952-0135, is likely to be shaped by several emerging trends and innovations:
1. Personalized Medicine
Advancements in genetic testing and biomarker identification may lead to more personalized treatment approaches, potentially affecting drug pricing and market segmentation.
2. Digital Health Integration
The integration of digital health technologies, such as continuous glucose monitoring systems, may enhance the value proposition of incretin-based drugs and influence pricing strategies.
3. Combination Therapies
The development of combination therapies that incorporate incretin-based drugs with other diabetes medications may create new market opportunities and pricing considerations.
4. Biosimilar Competition
As patents for some incretin-based drugs expire, the entry of biosimilar products may impact market dynamics and pricing strategies for drugs like NDC 81952-0135.
Regulatory Considerations
The regulatory environment plays a crucial role in shaping the market for pharmaceutical products, including NDC 81952-0135. Key regulatory considerations include:
FDA Approval Process
The rigorous FDA approval process ensures the safety and efficacy of drugs but also contributes to the high costs associated with bringing new medications to market.
Price Transparency Initiatives
Increasing pressure for price transparency in the pharmaceutical industry may impact future pricing strategies for drugs like NDC 81952-0135.
International Pricing Regulations
Differences in pricing regulations across countries can lead to variations in drug prices and market access strategies for global pharmaceutical companies.
Key Takeaways
- The global incretin-based drugs market, which includes NDC 81952-0135, is projected to grow at a CAGR of 6.8% from 2024 to 2029, reaching a valuation of USD 64.28 billion by 2029.
- Factors influencing drug pricing include R&D costs, competition, patent protection, regulatory environment, and manufacturing and distribution expenses.
- The competitive landscape for incretin-based drugs is characterized by the presence of major pharmaceutical companies employing various strategies to maintain market position.
- Generic competition and biosimilar entry can significantly impact pricing and market dynamics for branded drugs like NDC 81952-0135.
- Insurance coverage, reimbursement policies, and government programs play crucial roles in determining drug costs and market uptake.
- Future market trends, including personalized medicine, digital health integration, and combination therapies, may shape the landscape for incretin-based drugs.
- Regulatory considerations, including FDA approval processes and price transparency initiatives, continue to influence the pharmaceutical market.
FAQs
-
Q: What is the significance of the NDC code 81952-0135? A: The NDC code 81952-0135 is a unique identifier for a specific drug product, likely an incretin-based medication used in the treatment of type 2 diabetes.
-
Q: How is the global incretin-based drugs market expected to grow in the coming years? A: The market is projected to grow at a CAGR of 6.8% from 2024 to 2029, reaching a valuation of USD 64.28 billion by 2029.
-
Q: What are the main factors influencing the pricing of drugs like NDC 81952-0135? A: Key factors include research and development costs, competition, patent protection, regulatory environment, and manufacturing and distribution expenses.
-
Q: How might generic competition impact the pricing of NDC 81952-0135? A: Generic competition typically leads to price reductions for branded drugs and can significantly alter market dynamics and pricing strategies.
-
Q: What role do insurance and reimbursement policies play in the market for incretin-based drugs? A: Insurance coverage and reimbursement policies significantly influence drug costs to patients and can impact market uptake and pricing strategies for pharmaceutical companies.
Sources cited: [1] https://www.globenewswire.com/news-release/2024/02/20/2831955/0/en/Global-Incretin-Based-Drugs-Market-Report-2023-2029-with-Analysis-of-Leading-Market-Players-like-Eli-Lilly-and-Co-Boehringer-Ingelheim-Novo-Nordisk-and-AstraZeneca-Among-Others.html [2] https://www.nber.org/system/files/working_papers/w24387/w24387.pdf [3] https://www.nber.org/system/files/working_papers/w19367/w19367.pdf [4] https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information
More… ↓
